Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients
Hyuk Sung Kwon, Mina Hwang, Seong‐Ho Koh, Seong Hye Choi, Jae‐Hong Lee, Hyung‐Ji Kim, Sohee Park, Hyun‐Hee Park, Jee Hyang Jeong, Myung Hoon Han, Ji Young Kim
Abstract
We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions. Plasma p-tau217 and p-tau181 were measured in participants who were cognitively unimpaired (CU, n = 121), had mild cognitive impairment (n = 102), or dementia (n = 75) from two independent cohorts (Cohort 1: KBASE-V and Cohort 2: Asan) who underwent amyloid PET. In Cohort 1, plasma p-tau217 (area under the curve [AUC] = 0.938, P < 0.001) outperformed p-tau181 (AUC = 0.857, P < 0.001) in predicting amyloid PET positivity ( P difference < 0.001). In Cohort 2, p-tau217 (AUC = 0.893, P < 0.001) and p-tau181 (AUC = 0.856, P < 0.001) showed comparably good discrimination for predicting amyloid PET positivity ( P = 0.377). P-tau217 (AUC = 0.852, P < 0.001) and p-tau181 (AUC = 0.828, P < 0.001) demonstrated similarly good discriminations for predicting cognitive stage transition ( P difference = 0.093). Plasma p-tau217 and p-tau181 predicted amyloid PET positivity and cognitive stage transitions well. Plasma p-tau217 might perform better, especially in the early stages.